News
Dr Reddy's Laboratories
RDY · NATIONAL
$13.21−$0.02 (−0.15%)TodayMarket closed ·
Prev close $13.23
Latest news
- News
Dr Reddy's Laboratories Q2 EPS $0.12 Misses $0.16 Estimate, Sales $905.000M Miss $980.650M Estimate
- News
American Express, Eni On Deck Friday As Spending, Energy Demand Face Test
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- News
Dr Reddy's Laboratories Q1 2027 Earnings Call Transcript
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
- Press releasePRNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY
- Press releaseGlobe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy’s Laboratories Limited - RDY
- Press releaseBusiness Wire
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
- Press releaseBusiness Wire
Dr. Reddy’s Laboratories (RDY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation
- Press releaseBusiness Wire
Securities Fraud Investigation Into Dr. Reddy’s Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz
- Press releaseBusiness Wire
RDY SHAREHOLDER ALERT: Dr. Reddy’s Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
- Press releaseGlobe Newswire
DR. REDDY’S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud
- Press releaseBusiness Wire
Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States
- Press releasePRNewswire
Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky
- Press releaseGlobe Newswire
Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy’s Laboratories (RDY)
- Press releaseBusiness Wire
RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy’s Laboratories (RDY)
- Press releasePRNewswire
RDY SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Dr. Reddy's Laboratories
- Press releasePRNewswire
Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)
- NewsVandana Singh
Why Dr. Reddy's Sank: Profit Plunge, Semaglutide Setback And Trump's Tariff Threat
- News
Full Transcript: Dr Reddy's Laboratories Q4 2026 Earnings Call
- Press releaseBusiness Wire
Dr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
- Press releaseBusiness Wire
Dr. Reddy's Announces the First-to-Market Launch of Bosutinib Tablets 400mg, a Generic Equivalent of Bosulif®, in the United States
- Press releasePRNewswire
NYSE Content Update: Dell Technologies Reports 88% Revenue Increase YoY
- NewsNabaparna Bhattacharya
Dr. Reddy's Launches Generic Semaglutide In Canada, Expands GLP-1 Push
- Press releaseBusiness Wire
Dr. Reddy's Laboratories Launches its Generic Semaglutide Injection in Canada
- Press releaseBusiness Wire
Dr. Reddy's Laboratories Announces Health Canada Approval for Generic Semaglutide Injection in Canada
- News
'Canada Approves Its First Generic Version of Novo's Ozempic' - Bloomberg News
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsVandana Singh
India's Generic Wave Hits Ozempic And Wegovy As Prices Drop Sharply
- Press releaseBusiness Wire
Dr. Reddy's Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
- News
Coya Therapeutics Commences ~$11.1M Offering Of 2.522M Common Shares At $4.40/Share; Dr. Reddy's Laboratories And Greenlight Capital Are Investors In Offering
- News
'Dr Reddy's to Start Selling Generic Ozempic in India From March' - Bloomberg
- Press releaseBusiness Wire
Dr. Reddy's Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
- News
12 Health Care Stocks Moving In Monday's After-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.